Background: Alpha-fetoprotein (AFP) and its isoform AFP-L3 are well-established serum biomarkers for hepatocellular carcinoma (HCC), a common malignancy and a leading cause of cancer-related mortality worldwide. Current methods for measuring these biomarkers are primarily lectin-based assays including the liquid-phase binding assay (LiBA) and liquid chromatography–tandem mass spectrometry (LC-MS/MS), both of which have limitations in diagnostic sensitivity and clinical utility for samples with low AFP concentrations. We aimed to develop a lectin-independent LC-MS/MS method for quantifying fucosylated AFP proteins (AFP-Fuc%). Methods: We conducted analytical validation, including method comparisons, over 2 months. The analytical sensitivity and diagnostic performance of this method were evaluated using 525 human serum samples—235 from HCC patients and 290 from non-HCC individuals—and compared with those of LiBA, which measured AFP-L3 levels. Results: The LC-MS/MS method demonstrated acceptable within-laboratory imprecision (CVs < 17.1%) without detectable bias, carryover, or matrix effects. Our method exhibited a broader linear dynamic range (spanning five orders of magnitude) and 10-fold higher analytical sensitivity than LiBA. The diagnostic performance of our method was significantly superior to that of LiBA, particularly in patients with low AFP concentrations ( < 7 ng/mL, P < 0.001), with improved accuracy, sensitivity, and precision at a specificity of 96.2%. Conclusions The validated LC-MS/MS method demonstrated robust analytical performance and superior diagnostic accuracy over LiBA for HCC diagnosis while avoiding the inherent limitations of lectin-based assays. Our LC-MS/MS assay shows promise for early HCC detection and may contribute to enhanced patient care.

Background/Aims: Esophageal transit scintigraphy is a non-invasive nuclear medicine imaging modality for people with esophageal transit problems. In particular, changes in esophageal motor function can be evaluated non-invasively before and after the treatment in patients undergoing peroral endoscopic myotomy (POEM) for achalasia. This study compared the changes in several parameters of esophageal transit and manometry in patients with achalasia who underwent POEM. Methods: This study retrospectively analyzed prospectively collected data from POEM participants. We included 38 patients with achalasia who underwent high-resolution manometry and esophageal transit scintigraphy before POEM and after POEM from 2016 to 2023. Results: All patients had clinical treatment successfully (Eckardt score < 3). Lower esophageal sphincter (LES) pressures were significantly reduced after POEM, including basal resting LES pressure and integrated relaxation pressure (P < 0.001).Esophageal emptying, as assessed by the residual fraction of retained radioactivity at 10 seconds after isotope ingestion, improved from 54.3% to 27.3% (P < 0.001). Analysis of the change in time-to-peak on the time-radioactivity curve showed that it shortened significantly in the upper and middle portions of the esophagus (P < 0.05) but not in the lower portion.The Eckardt symptom score significantly correlated with pre-POEM integrated relaxation pressure (P < 0.05). Post-POEM, the symptom score significantly correlated with time-to-peak of the upper portion of the esophagus (P < 0.05). Conclusions Patients with achalasia who received POEM showed improved not only manometric LES parameters but also esophageal transit. Analysis of the radiation curve’s time-to-peak showed that improved retention in the upper portion is an indicator of symptoms improvement in patients who underwent POEM.

Background: and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment. Methods: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study. Results: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22. Conclusions Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.

Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.

Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.

Background: and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment. Methods: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study. Results: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22. Conclusions Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.

Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.

Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.

Oxidative stress, a key factor in the progression of brain diseases, induces apoptosis through multiplepathways. This study investigates the protective effects of Euonymus elatus, a traditional Korean remedy for conditions such as atherosclerosis, dysmenorrhea, and pain, on neuronal cells under oxidative stress. Excess glutamate was used to model oxidative stress, resulting in elevated reactive oxygen species (ROS), increased intracellular calcium (Ca²⁺), reduced mitochondrial membrane potential, and decreased activity of glutathionerelated enzymes, including glutathione reductase (GR) and glutathione peroxidase (GPx). Experimental results revealed that E. elatus extract provided significant cytoprotective effects. The extracts improved cell viability in MTT assays, reduced ROS and Ca²⁺ levels, restored mitochondrial membrane potential, and enhanced the activity of GR and GPx. These findings highlight the potential of E. elatus as a therapeutic candidate for mitigating oxidative stress and treating neurodegenerative disorders, such as Alzheimer’s disease.

Background: and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment. Methods: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study. Results: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22. Conclusions Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.